Clay  Thorp net worth and biography

Clay Thorp Biography and Net Worth

Clay co-founded PhaseBio Pharmaceuticals in 2002 and has served as a member of the company’s board of directors since that time. He has served as Chairman of PhaseBio since November 2014. Since 1995, Clay has co-founded seven life sciences companies, including PhaseBio. He also co-founded Hatteras Venture Partners in 2000, where he has been instrumental in building the firm from its origins with a $3 million seed fund to a venture capital partnership that manages over $350 million across five funds. Clay was co-founder, CEO and Chairman of Synthematix, Inc., a chemistry informatics company acquired in April 2005 by Symyx Technologies. He was the co-founder and Head of Corporate Development for Novalon Pharmaceutical Corporation, where he led financing efforts and was Head of Business Development from inception until Novalon’s sale to Karo Bio for $106.7 million in May 2000. Prior to Novalon, Clay was the co-founder and President of Xanthon, Inc., a bioinformatics company with electro-chemical detection technology for direct analysis of DNA, RNA and proteins. Clay currently serves as Chairman of GeneCentric Diagnostics and on the boards of Clearside Biomedical, Curoverse, Lysosomal Therapeutics and Orig3n. He received a BA in mathematics and art history from the University of North Carolina at Chapel Hill and a Masters of Public Policy from Harvard University.

What is Clay Thorp's net worth?

The estimated net worth of Clay Thorp is at least $0.00 as of September 25th, 2023. Mr. Thorp owns 40,522 shares of PhaseBio Pharmaceuticals stock worth more than $0 as of March 28th. This net worth approximation does not reflect any other investments that Mr. Thorp may own. Learn More about Clay Thorp's net worth.

How do I contact Clay Thorp?

The corporate mailing address for Mr. Thorp and other PhaseBio Pharmaceuticals executives is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. PhaseBio Pharmaceuticals can also be reached via phone at (610) 981-6500 and via email at [email protected]. Learn More on Clay Thorp's contact information.

Has Clay Thorp been buying or selling shares of PhaseBio Pharmaceuticals?

Clay Thorp has not been actively trading shares of PhaseBio Pharmaceuticals over the course of the past ninety days. Most recently, on Wednesday, August 18th, Clay Thorp bought 10,000 shares of PhaseBio Pharmaceuticals stock. The stock was acquired at an average cost of $3.00 per share, with a total value of $30,000.00. Learn More on Clay Thorp's trading history.

Who are PhaseBio Pharmaceuticals' active insiders?

PhaseBio Pharmaceuticals' insider roster includes Glen Burkhardt (VP), and Clay Thorp (Director). Learn More on PhaseBio Pharmaceuticals' active insiders.

Clay Thorp Insider Trading History at PhaseBio Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/18/2021Buy10,000$3.00$30,000.00View SEC Filing Icon  
11/24/2020Buy5,000$3.60$18,000.00
7/1/2019Sell2,908$14.00$40,712.00View SEC Filing Icon  
6/18/2019Sell400$14.00$5,600.00View SEC Filing Icon  
12/4/2018Buy4,000$3.13$12,520.00View SEC Filing Icon  
See Full Table

Clay Thorp Buying and Selling Activity at PhaseBio Pharmaceuticals

This chart shows Clay Thorp's buying and selling at PhaseBio Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

PhaseBio Pharmaceuticals Company Overview

PhaseBio Pharmaceuticals logo
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

2 Week Range

Now: N/A

Volume

2,910 shs

Average Volume

848,888 shs

Market Capitalization

$3.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.57